10,800 Shares in Replimune Group, Inc. $REPL Purchased by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. bought a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 10,800 shares of the company’s stock, valued at approximately $100,000.

Other hedge funds have also made changes to their positions in the company. Candriam S.C.A. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at approximately $1,594,000. Nan Fung Trinity HK Ltd. acquired a new position in shares of Replimune Group in the 2nd quarter valued at $4,325,000. Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group in the 2nd quarter valued at $403,000. AlphaQuest LLC grew its holdings in shares of Replimune Group by 99.9% during the 2nd quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock worth $92,000 after purchasing an additional 4,925 shares during the period. Finally, TD Asset Management Inc increased its position in shares of Replimune Group by 18.7% during the 2nd quarter. TD Asset Management Inc now owns 327,452 shares of the company’s stock worth $3,042,000 after purchasing an additional 51,600 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Up 0.1%

Shares of NASDAQ REPL opened at $8.99 on Friday. The stock has a market cap of $705.18 million, a P/E ratio of -2.60 and a beta of 0.80. The company has a current ratio of 6.31, a quick ratio of 6.94 and a debt-to-equity ratio of 0.26. Replimune Group, Inc. has a 12-month low of $2.68 and a 12-month high of $17.00. The business’s fifty day simple moving average is $6.45 and its 200-day simple moving average is $7.42.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.03). As a group, equities analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of recent analyst reports. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and upped their target price for the company from $4.00 to $18.00 in a research report on Monday, October 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Replimune Group in a report on Tuesday. Jefferies Financial Group dropped their target price on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. BMO Capital Markets lowered Replimune Group from an “outperform” rating to an “underperform” rating and cut their target price for the company from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Finally, Barclays cut Replimune Group from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $17.00 to $3.00 in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.